Cin Cor Pharma, Inc. CINC
We take great care to ensure that the data presented and summarized in this overview for CinCor Pharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CINC
View allLatest Institutional Activity in CINC
Top Purchases
Top Sells
About CINC
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.
Insider Transactions at CINC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 24
2023
|
5 Am Partners Vi, LLC > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
4,937,646
-100.0%
|
-
|
|
Feb 24
2023
|
James Healy Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
6,073,949
-100.0%
|
-
|
|
Feb 24
2023
|
James Healy Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
19,608
-100.0%
|
-
|
|
Feb 24
2023
|
James Healy Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
9,803
-33.33%
|
-
|
|
Feb 24
2023
|
Mason Freeman Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
100
-100.0%
|
-
|
|
Feb 24
2023
|
Mason Freeman Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
40,000
-100.0%
|
-
|
|
Feb 24
2023
|
Mason Freeman Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,494
-5.87%
|
-
|
|
Feb 24
2023
|
Catherine Pearce Chief Operating Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
1,500
-100.0%
|
-
|
|
Feb 24
2023
|
Catherine Pearce Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,000
-100.0%
|
-
|
|
Feb 24
2023
|
Catherine Pearce Chief Operating Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
140,149
-90.33%
|
-
|
|
Feb 24
2023
|
Michael Wayne Kalb EVP & Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
202,437
-100.0%
|
-
|
|
Feb 24
2023
|
Marc De Garidel Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
200,000
-100.0%
|
-
|
|
Feb 24
2023
|
Marc De Garidel Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
12,500
-5.88%
|
-
|
|
Jan 26
2023
|
Michael Wayne Kalb EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
177,000
+46.65%
|
-
|
|
Jan 26
2023
|
Catherine Pearce Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+8.82%
|
-
|
|
Jan 26
2023
|
Marc De Garidel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+48.48%
|
-
|
|
Jan 26
2023
|
Mason Freeman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+48.48%
|
-
|
|
Jan 11
2023
|
Catherine Pearce Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,997
-2.77%
|
$111,916
$28.75 P/Share
|
|
Jan 11
2023
|
Catherine Pearce Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,235
+8.41%
|
-
|
|
Nov 28
2022
|
James Healy Director |
SELL
Open market or private sale
|
Indirect |
6,000
-100.0%
|
$84,000
$14.32 P/Share
|